Editor's Note: This video was filmed on May 7th.
Corcept Therapeutics (NASDAQ:CORT) shares were slammed last week after a phase 3 trial for mifepristone to treat patients with depression was stopped after an independent data monitoring committee indicated that the drug would probably not provide a statistically significant benefit to currently enrolled patients. The data was from 266 patients in a study that was intended to expand up to 450 patients, but instead of sinking more money into the study by continuing, Corcept's management decided to end the trial and focus on other potential indications.
Indications as diverse as breast cancer, post-traumatic stress disorder, and alcohol dependence.
What to make of this diversity? Does it signify a management that is scattershotting?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give you their answer and their thoughts on the company.
David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.